title: [Immunohistochemical evaluation of somatostatin receptor subtypes in surgical pathology specimens of neuroendocrine tumors].
abstract: The clinical development of specific/selective or more potent analogues of somatostatin has made the evaluation of somatostatin receptor subtypes in archival specimens or 10% formalin-fixed and paraffin-embedded specimens of neuroendocrine tumor (NET) critical to conferring the maximum clinical benefits on NET patients. Immunohistochemistry of somatostatin receptor subtypes could contribute to profiling their expression patterns in these patients. Therefore, surgical pathologists are expected to be asked to immunostain and evaluate somatostatin receptor subtypes in NET specimens in the near future by clinicians. However, there are problems associated with immunohistochemistry of somatostatin receptor subtypes, in particular with their evaluation and interpretation. Therefore, both pathologists and clinicians involved in the care or management of NET patients should be aware of the advantages and limitations of immunohistochemical evaluation of somatostatin receptor subtypes in order to achieve the most efficient treatment outcome for patients.
authors.affiliation: Department of Pathology, Tohoku University School of Medicine, 2-1 Seiryou-machi, Aoba-ku, 980-8575 Sendai, Japan. hsasano@patholo2.med.tohoku.ac.jp
authors.forename: H
authors.initials: H
authors.lastname: Sasano
authors.forename: S
authors.initials: S
authors.lastname: Iida
authors.forename: A
authors.initials: A
authors.lastname: Kasajima
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D006801:Humans; D007150:Immunohistochemistry; D018358:Neuroendocrine Tumors / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D011237:Predictive Value of Tests; D017481:Receptors, Somatostatin / Q000032:analysis*; D013004:Somatostatin / Q000031:analogs & derivatives
chemical_list: D000970:Antineoplastic Agents; D017481:Receptors, Somatostatin; D013004:Somatostatin
references.citation: Mod Pathol. 2007 Nov;20(11):1172-82
references.pmid: 17873898
references.citation: Front Neuroendocrinol. 1999 Jul;20(3):157-98
references.pmid: 10433861
references.citation: Metabolism. 1992 Sep;41(9 Suppl 2):104-10
references.pmid: 1355582
references.citation: Best Pract Res Clin Gastroenterol. 2005 Aug;19(4):535-51
references.pmid: 16183526
references.citation: Nat Rev Endocrinol. 2010 Apr;6(4):188-9
references.pmid: 20336162
references.citation: Neuroendocrinology. 2009;89(3):308-14
references.pmid: 19307732
references.citation: Anticancer Res. 2007 Jul-Aug;27(4B):2231-9
references.pmid: 17695508
references.citation: Virchows Arch. 2001 Dec;439(6):787-97
references.pmid: 11787852
references.citation: Ann N Y Acad Sci. 2004 Apr;1014:13-27
references.pmid: 15153416
references.citation: Lancet. 1998 Sep 5;352(9130):799-805
references.pmid: 9737302
references.citation: Intern Med J. 2010 Jun;40(6):453-8
references.pmid: 20636828
references.citation: Endocr J. 2005 Oct;52(5):605-11
references.pmid: 16284440
references.citation: Virchows Arch. 2002 May;440(5):461-75
references.pmid: 12021920